An outstanding management team composed of high-level talents with overseas pharmaceutical R&D background and extensive commercialization experience.
-
Management Team -
Honors CourseUtidelone has been selected twice for oral presentations at the ASCO annual meeting and approved in 2021 for the treatment of mBC.
-
PartneringWe are actively selecting partners. Please contact our BD team via bd@biostar-pharma.com.
-
Who we areAs an innovative cancer drug company driven by synthetic biology technology, Beijing Biostar successfully listed in Hong Kong.
News
-
2025-09-12Company News
First Patient Dosed in Phase II/III Multiple Region Clinical Trial (MRCT) of Utidelone Capsules as First-Line Treatment for Advanced Gastric Cancer -
2025-09-11Company NewsFirst Patient Dosed in Global, Multicenter Clinical Trial | Utidelone Capsule for the Treatment of Advanced Ovarian Cancer
-
2025-07-14Company NewsFirst Patient Enrolled in Phase III Trial of Utidelone Capsule for Adjuvant Therapy in Triple-Negative Breast Cancer
-
2025-05-15Company NewsAnother IND Approval of International Multicenter Study | Phase II/III Clinical Trial of Utidelone Capsule for Platinum-Resistant Ovarian Cancer
-
2025-04-24Company NewsBeijing Biostar To Present Multiple Clinical Research Achievements of Utidelone at ASCO 2025 with an Oral Presentation
-
2025-02-05Company NewsBeijing Biostar received US FDA’s IND approval to conduct a multiple-region-clinical-trial (MRCT) of Utidelone Capsule for the first-line treatment of advanced gastric cancer
-
2024-11-14Company NewsBiostar to collaborate with Baheal Medical to accelerate the commercialization process of Utidelone
-
2024-10-31Company NewsBeijing Biostar successfully landed on the main board of the Hong Kong Stock Exchange, synthetic biology leads the new era of innovative drug research and development
-
2024-09-30Company NewsPreliminary data released from a clinical study of Utidelone for the first-line treatment of advanced pancreatic cancer
